sever
acut
respiratori
syndrom
sar
epidem
character
increas
pathogen
elderli
due
earli
exacerb
innat
host
respons
sarscov
zoonot
pathogen
enter
human
popul
intermedi
host
like
palm
civet
prevent
futur
introduct
zoonot
sarscov
strain
subsequ
transmiss
human
popul
heterolog
diseas
model
need
test
efficaci
vaccin
therapeut
late
human
zoonot
isol
show
human
zoonot
sarscov
strain
infect
cynomolgu
macaqu
result
radiolog
well
histopatholog
chang
similar
seen
mild
human
case
viral
replic
higher
anim
infect
late
human
phase
isol
compar
zoonot
isol
signific
differ
number
host
gene
differenti
regul
host
respons
three
sarscov
strain
top
pathway
function
similar
appar
earli
infect
major
gene
associ
interferon
signal
pathway
studi
character
critic
diseas
model
evalu
licensur
therapeut
strategi
sarscov
human
use
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
result
human
infect
case
fatal
rate
sarscov
zoonot
pathogen
origin
bat
either
enter
human
popul
directli
andor
cycl
palm
civet
raccoon
dog
intermedi
host
advanc
age
significantli
associ
increas
sarsrel
pathogen
death
due
rapidli
progress
respiratori
compromis
acut
respiratori
distress
syndrom
ard
base
epidemiolog
studi
sarscov
epidem
character
differ
phase
zoonot
earli
middl
late
phase
zoonot
phase
character
strain
isol
palm
civet
raccoon
dog
live
anim
market
earli
phase
character
sever
independ
human
case
like
due
zoonot
transmiss
middl
phase
character
initi
humantohuman
transmiss
wherea
late
phase
character
effici
humantohuman
transmiss
extens
global
spread
countri
sarscov
spike
glycoprotein
identifi
main
mediat
viru
entri
host
rang
bind
receptor
angiotensin
enzym
high
mutat
rate
glycoprotein
observ
differ
isol
anim
human
sever
amino
acid
chang
identifi
critic
transit
animaltohuman
humantohuman
transmiss
glycoprotein
also
identifi
major
target
protect
immun
main
focu
vaccin
develop
vaccin
candid
develop
use
nearli
ident
isol
late
phase
epidem
clear
whether
late
phase
isol
provid
robust
protect
infect
zoonot
earli
human
phase
isol
like
sourc
futur
outbreak
therefor
heterolog
challeng
model
need
test
crossprotect
efficaci
vaccin
candid
current
sever
anim
model
sarscov
exist
includ
mice
hamster
ferret
nonhuman
primat
model
use
pathogenesi
studi
well
vaccin
develop
major
studi
focus
isol
late
phase
outbreak
fact
heterolog
challeng
mice
vaccin
late
phase
glycoprotein
offer
partial
protect
previous
character
vitro
vivo
virul
isogen
panel
recombin
sarscov
isol
bear
glycoprotein
zoonot
earli
middl
late
phase
isol
late
earli
human
phase
virus
replic
high
titer
human
ciliat
airway
epitheli
cultur
wherea
zoonot
isol
interestingli
earli
human
zoonot
phase
isol
lethal
age
mous
model
result
sever
lung
infect
progress
earli
organ
phase
ard
death
studi
compar
pathogenesi
three
recombin
sarscov
isol
bear
glycoprotein
zoonot
earli
late
phase
isol
cynomolgu
macaqu
urbani
strain
recombin
urbani
sarscov
molecular
clone
previous
test
nonhuman
primat
model
serv
control
current
studi
clinic
virolog
histolog
paramet
well
host
respons
compar
fulli
understand
effect
glycoprotein
variat
viru
replic
host
respons
sarscov
infect
ultim
goal
character
heterolog
challeng
model
sarscov
vaccin
develop
importantli
virus
replic
near
similar
titer
induc
similar
patholog
chang
mild
diseas
demonstr
avail
heterolog
challeng
virus
futur
vaccin
studi
group
cynomolgu
macaqu
challeng
via
intratrach
intranas
rout
recombin
urbani
sarscov
strain
overt
clinic
symptom
seen
infect
anim
addit
fever
detect
clinic
exam
day
post
infect
minor
transient
lymphopenia
seen
day
pi
infect
anim
data
shown
signific
chang
observ
blood
chemistri
respiratori
diseas
develop
also
analyz
radiograph
imag
xray
first
sign
mild
interstiti
pulmonari
infiltr
peribronchi
mark
lung
anim
infect
urbani
earli
day
pi
data
shown
day
pi
radiolog
chang
urbani
infect
anim
similar
day
addit
decreas
conspicu
caudal
vena
cava
cvc
fig
chang
last
day
least
anim
radiolog
chang
infect
anim
similar
urbani
infect
anim
interestingli
one
anim
show
clear
progress
day
small
ventralmost
consolid
left
middlecaud
lung
right
later
view
heavi
peribronchi
mark
fig
notabl
improv
seen
day
mild
interstiti
infiltr
central
unsharp
cvc
margin
later
view
surprisingli
infect
result
signific
radiolog
chang
earli
infect
although
mild
increas
interstiti
infiltr
could
observ
anim
day
fig
gross
patholog
find
necropsi
day
pi
includ
enlarg
cervic
bronchial
lymph
node
splenomegali
adher
lung
lobe
pleura
lesion
notic
lung
anim
viru
replic
three
sarscov
strain
mainli
restrict
respiratori
tract
trachea
bronchi
lung
lobe
low
level
replic
spleen
cervic
bronchial
lymph
node
fig
b
viral
replic
peak
respiratori
tract
day
pi
fig
reduct
viru
titer
number
viru
posit
tissu
day
pi
fig
similar
find
mice
infecti
viru
could
isol
day
pi
tissu
data
shown
viru
titer
urbani
infect
anim
gener
log
higher
compar
infect
anim
viral
rna
could
detect
lung
infect
anim
day
pi
data
shown
level
viral
rna
similar
sarscov
strain
time
point
decreas
time
observ
viral
titer
measur
viru
shed
nasal
oral
rectal
swab
assay
infecti
viru
nasal
swab
viru
titer
peak
day
could
detect
day
pi
fig
viru
titer
oral
swab
peak
day
detect
titer
day
pi
fig
low
level
viru
replic
could
observ
rectal
swab
anim
fig
anim
infect
three
strain
sarscov
show
mild
inflamm
within
submucosa
occasion
extens
mucosa
trachea
bronchi
day
pi
compar
control
fig
c
e
g
k
fig
mild
perivascular
inflamm
observ
within
lung
well
multifoc
minim
mild
increas
lymphocyt
macrophag
fewer
neutrophil
eosinophil
within
alveolar
septa
alveoli
fig
rare
alveolar
fibrin
edema
minim
hemorrhag
observ
urbani
viral
protein
could
detect
tracheal
epitheli
cell
alveolar
pneumocyt
day
pi
fig
f
anim
infect
either
strain
show
multifoc
mild
moder
sever
increas
compar
urbani
strain
lesion
subacut
eosinophil
pneumon
alveol
occasion
bronchiti
bronchiol
day
pi
fig
anim
perivascul
edema
observ
along
occasion
alveolar
fibrin
deposit
type
ii
pneumocyt
hyperplasia
viral
protein
could
detect
tracheal
epitheli
cell
low
number
macrophag
alveolar
pneumocyt
lung
fig
j
viral
protein
detect
trachea
fig
despit
presenc
infecti
viru
titrat
fig
could
detect
alveolar
pneumocyt
lung
day
pi
fig
day
pi
persist
perivascul
peribronchiol
peribronch
observ
decreas
incid
alveolar
septal
pneumon
alveol
anim
infect
sarscov
strain
inflammatori
cell
consist
mostli
macrophag
lymphocyt
neutrophil
previous
show
host
respons
differ
mice
infect
differ
spike
glycoprotein
variant
clinic
differ
observ
virus
use
studi
viru
replic
differ
fig
suggest
may
differ
host
respons
compar
host
gene
express
lung
tissu
viru
infect
group
host
respons
control
anim
differenti
express
gene
observ
day
pi
highest
number
differenti
express
gene
urbani
infect
anim
fig
day
pi
major
differenti
express
gene
associ
hcsz
infect
common
three
virus
fig
wherea
major
gene
associ
urbani
infect
uniqu
order
better
understand
biolog
function
associ
host
respons
sarscov
infect
function
annot
determin
signific
differenti
express
gene
use
ipa
interestingli
although
urbani
infect
result
higher
number
differenti
express
gene
compar
infect
anim
top
function
canon
pathway
ident
sarscov
strain
top
function
includ
antimicrobi
respons
inflammatori
respons
organism
injuri
fig
wherea
top
canon
pathway
includ
interferon
signal
irf
activ
pattern
recognit
receptor
pathway
fig
fold
chang
gene
involv
pathway
gener
higher
urbani
infect
anim
compar
infect
anim
tabl
includ
interferon
induc
gene
like
interferoninduc
protein
tetratricopeptid
repeat
ifit
myxoviru
resist
other
well
signal
transduc
activ
transcript
stat
highest
differenti
express
gene
includ
order
confirm
mrna
express
kinet
cytokin
translat
level
protein
level
pro
antiinflammatori
cytokin
determin
lung
homogen
plasma
control
sarscov
infect
anim
mrna
express
increas
sarscov
infect
anim
signific
therefor
includ
analys
describ
howev
agreement
overal
host
gene
express
kinet
level
lung
tissu
elev
anim
infect
differ
sarscov
strain
compar
control
anim
day
pi
peak
day
pi
fig
day
pi
data
shown
cytokin
level
blood
gener
correl
found
lung
except
peak
day
pi
fig
signific
differ
found
sarscov
strain
sarscov
zoonot
pathogen
caus
sever
respiratori
diseas
human
evolut
viru
throughout
epidem
character
high
mutat
rate
glycoprotein
adapt
correl
increas
pathogen
human
previous
show
mutat
glycoprotein
result
differ
virul
age
mous
model
sarscov
infect
mutat
also
differenti
affect
replic
primari
human
airway
epitheli
cultur
show
contrast
zoonot
sarscov
strain
human
strain
replic
effici
cultur
studi
use
panel
recombin
sarscov
bear
variant
glycoprotein
develop
new
model
sarscov
infect
nonhuman
primat
could
use
test
vaccin
candid
therapeut
heterolog
challeng
sever
group
shown
cynomolgu
macaqu
infect
sarscov
although
clinic
present
variabl
howev
initi
studi
control
age
anim
advanc
age
significantli
increas
sever
sarscov
infect
correl
increas
morbid
mortal
human
recent
studi
sarscov
infect
year
old
cynomolgu
macaqu
result
decreas
activ
mildli
labor
breath
anim
addit
pulmonari
consolid
observ
well
diffus
alveolar
damag
studi
infect
year
old
cynomolgu
macaqu
recombin
sarscov
bear
glycoprotein
variant
howev
increas
age
result
overt
clinic
symptom
cynomolgu
macaqu
model
comparison
previous
infect
cynomolgu
macaqu
newli
emerg
influenza
viru
result
increas
respiratori
rate
nasal
discharg
mildmoder
radiograph
chang
gross
patholog
lesion
lung
one
possibl
explan
differ
observ
sarscov
studi
use
differ
sarscov
strain
current
studi
use
urbani
strain
wherea
smit
et
al
use
differ
strain
sarscov
isol
one
earliest
hong
kong
patient
contain
sever
mutat
throughout
genom
observ
aa
chang
urbani
strain
may
affect
pathogenesi
cynomolgu
macaqu
model
studi
recombin
sarscov
strain
bear
variant
glycoprotein
construct
urbani
background
previous
hypothes
recombin
sarscov
strain
would
show
differ
replic
nonhuman
primat
due
fact
urbani
strain
replic
effici
human
airway
epithelium
wherea
zoonot
strain
includ
agreement
observ
human
case
sarscov
infect
infect
late
phase
sarscov
strain
result
sever
diseas
effici
transmiss
compar
mild
sporad
case
zoonot
phase
epidem
shown
glycoprotein
strain
adapt
effici
bind
receptor
inde
epidem
urbani
strain
replic
higher
titer
compar
shed
virus
could
detect
primarili
nasal
oral
swab
measur
potenti
transmiss
howev
unlik
infect
mice
differ
found
cell
tropism
sarscov
strain
target
primarili
type
ii
pneumocyt
viral
antigen
detect
trachea
infect
anim
recoveri
infecti
viru
tissu
suggest
absenc
antigen
unlik
due
differ
tropism
rather
due
limit
detect
addit
sarscov
glycoprotein
implic
downregul
express
downregul
caus
deregul
reninangiotensin
system
exagger
acut
lung
failur
hypothes
sarscov
glycoprotein
differ
zoonot
human
phase
epidem
may
differenti
downregul
result
observ
disconnect
viru
replic
pathogenesi
howev
unlik
mous
model
differ
express
could
observ
gene
express
immunohistochemistri
data
shown
cynomolgu
macaqu
possibl
due
mild
diseas
progress
observ
current
model
glycoprotein
major
virul
factor
exclud
addit
mutat
rest
genom
strain
could
necessari
virul
phenotyp
cynomolgu
macaqu
model
current
model
gross
patholog
lesion
evid
lung
anim
interestingli
sarscov
infect
result
radiolog
chang
includ
pulmonari
infiltr
peribronchi
mark
earli
infect
although
observ
earlier
similar
seen
mild
human
case
well
anim
infect
rout
contrast
anim
infect
intrabronchi
ib
rout
show
earli
radiolog
chang
lower
lung
lobe
one
explan
earli
detect
radiolog
chang
current
model
anim
infect
intratrach
high
dose
sarscov
intratrach
instil
result
presenc
high
viru
load
trachea
bronchi
anim
subsequ
peribronchi
mark
observ
earli
infect
natur
infect
human
case
would
result
exposur
lower
viru
dose
less
effici
rout
contrast
infect
intrabronchi
rout
result
initi
viru
replic
interstitium
result
radiolog
chang
lower
lobe
earli
infect
radiolog
chang
correl
observ
histopatholog
lung
model
exhibit
sever
diffus
alveolar
damag
dad
edema
hyalin
membran
format
associ
sever
human
case
sarscov
infect
alveol
edema
fibrin
deposit
type
ii
pneumocyt
hyperplasia
observ
anim
infect
strain
urbani
infect
anim
agreement
observ
mice
increas
sever
lung
patholog
also
correl
viru
replic
lung
urbani
strain
replic
log
higher
titer
compar
strain
human
case
upregul
ifn
pathway
plu
robust
antivir
ifnstimul
gene
isg
express
observ
earli
sarscov
infect
addit
sever
anim
model
shown
acut
exacerb
host
respons
result
acut
lung
injuri
current
studi
observ
earli
upregul
gene
associ
ifn
signal
activ
ifn
relat
pathway
earli
upregul
previous
shown
mous
nonhuman
primat
model
sarscov
infect
well
influenza
infect
particular
earli
enhanc
express
interferoninduc
monocyt
chemoattract
correl
advers
outcom
sarscov
infect
human
also
highli
upregul
studi
unfortun
due
animaltoanim
variat
differenti
express
gene
could
identifi
day
pi
interestingli
differ
observ
pathway
involv
sarscov
strain
although
number
gene
involv
pathway
higher
urbani
infect
anim
compar
infect
anim
addit
foldchang
also
greater
follow
infect
urbani
strain
compar
higher
upregul
host
gene
follow
urbani
infect
correl
observ
replic
agreement
observ
host
gene
respons
express
inflammatori
antiinflammatori
mediat
upregul
lung
infect
anim
day
pi
upregul
gene
previous
observ
serum
peripher
blood
mononuclear
cell
human
case
sar
addit
also
found
upregul
plasma
influenza
infect
macaqu
conclus
studi
demonstr
cynomolgu
macaqu
infect
zoonot
earli
human
epidem
phase
sarscov
strain
shown
presenc
infecti
viru
respiratori
tract
day
addit
show
infect
result
prolong
shed
viru
nasal
oral
secret
day
post
challeng
potenti
method
transmiss
final
infect
sarscov
strain
induc
host
respons
earli
infect
data
show
new
cynomolgu
macaqu
model
import
test
efficaci
vaccin
candid
therapeut
antigen
distinct
sarscov
strain
date
major
vaccin
studi
focus
epidem
urbani
strain
provid
limit
protect
heterolog
strain
especi
senesc
popul
risk
sever
diseas
epidem
sarscov
strain
extinct
howev
zoonot
strain
may
still
emerg
anim
reservoir
like
bat
palmcivet
raccoondog
therefor
sarscov
vaccin
confer
longterm
protect
replic
shed
epidem
strain
zoonot
strain
may
emerg
gener
character
recombin
sarscov
bear
variant
glycoprotein
urbani
describ
previous
virus
propag
vero
cell
dulbecco
minim
essenti
medium
dmem
invitrogen
supplement
fetal
bovin
serum
lglutamin
penicillin
iuml
streptomycin
iuml
humidifi
co
incub
work
perform
class
ii
biosafeti
cabinet
condit
rml
dir
nih
healthi
adult
femal
cynomolgu
macaqu
macaca
fasciculari
handl
contain
laboratori
rml
dir
nih
research
conduct
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
facil
research
conduct
rml
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
approv
olaw
assur
research
conduct
protocol
approv
institut
anim
care
use
committe
iacuc
rml
step
taken
amelior
welfar
avoid
suffer
anim
accord
weatheral
report
use
nonhuman
primat
recommend
anim
hous
adjoin
individu
primat
cage
allow
social
interact
control
condit
humid
temperatur
light
dark
cycl
food
water
avail
ad
libitum
anim
monitor
preand
postinfect
fed
commerci
monkey
chow
treat
fruit
twice
daili
train
personnel
environment
enrich
consist
commerci
toy
procedur
conduct
train
personnel
supervis
veterinarian
invas
clinic
procedur
perform
anim
anesthet
earli
endpoint
criteria
specifi
iacuc
approv
score
paramet
use
determin
anim
human
euthan
thirti
femal
cynomolgu
macaqu
macaca
fasciculari
age
weigh
kg
distribut
evenli
regard
age
weight
four
group
anim
per
viru
group
anim
control
group
anim
infect
either
urbani
anesthesia
combin
intratrach
ml
intranas
ml
per
nostril
instal
suspens
contain
plaqu
form
unit
pfu
per
ml
dmem
total
infecti
dose
pfu
differ
sarscov
strain
three
anim
mock
infect
viru
cultur
medium
fcsp
anim
anesthet
challeng
clinic
examin
temperatur
respir
rate
chest
radiograph
blood
draw
swab
nasal
oral
rectal
mucosa
day
pi
three
anim
mobil
digit
radiographi
unit
flat
panel
digit
detector
sound
technolog
trudr
portabl
xray
gener
poskom
model
pxphf
use
acquir
chest
radiograph
system
oper
veterinari
specif
softwar
system
vetpac
anim
posit
ventrodors
radiographi
use
lexan
vshape
thorac
position
radiograph
view
acquir
includ
ventrodors
right
later
left
later
thorac
imag
anesthesia
digit
imag
interpret
assign
numer
score
veterinari
radiologist
blind
studi
design
jm
score
scale
base
sever
radiograph
chang
assign
set
radiograph
ventrodors
right
later
left
later
time
point
radiograph
evalu
score
use
follow
criteria
grade
normal
examin
grade
mild
interstiti
pulmonari
infiltr
grade
moder
interstiti
infiltr
may
includ
partial
cardiac
border
effac
small
area
pulmonari
consolid
alveolar
pattern
air
bronchogram
grade
pulmonari
consolid
primari
lung
patholog
seen
progress
grade
lung
patholog
total
white
blood
cell
wbc
count
lymphocyt
platelet
reticulocyt
red
blood
cell
count
hemoglobin
hematocrit
valu
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
determin
edta
blood
hemavet
laserbas
hematolog
analyz
drew
scientif
serum
biochemistri
analyz
heparin
blood
use
blood
chemistri
analyz
abbott
point
care
use
cartridg
urea
nitrogen
bun
glucos
chlorid
sodium
potassium
hematocrit
hemoglobin
ph
base
excess
beecf
anion
gap
valu
determin
creatinin
valu
evalu
use
crea
cartridg
concentr
gcsf
gmcsf
ifnc
tgfa
tnfa
vegf
plasma
anim
determin
day
pi
lung
homogen
day
pi
use
nonhuman
primat
cytokin
milliplex
map
kit
millipor
corp
describ
manufactur
sampl
read
use
bioplex
system
biorad
nasal
oral
rectal
swab
collect
store
ml
dmem
vortex
second
tissu
sampl
weigh
homogen
equival
volum
dmem
gener
solut
solut
centrifug
rpm
aerosol
contain
tabl
top
centrifug
min
supernat
swab
tissu
homogen
serial
dilut
dmem
ml
volum
dilut
place
onto
monolay
cell
sixwel
plate
follow
hour
incub
cell
overlaid
agarosecontain
medium
two
day
later
plate
stain
crystal
violet
plaqu
count
titer
calcul
plaqu
form
unit
pfu
per
ml
gr
swab
tissu
respect
titer
graph
use
graphpad
prism
tissu
inactiv
fix
phosphatebuff
formalin
least
day
prior
process
convent
method
embed
paraffin
section
mm
thick
hematoxylin
eosin
stain
slide
evalu
veterinari
pathologist
dg
tissu
immunohistochemistri
stain
discoveri
xt
autom
stainer
ventana
medic
system
use
antisarsnucleoprotein
antibodi
imgenex
dab
map
detect
kit
ventana
medic
system
nonimmun
rabbit
igg
use
neg
stain
control
tissu
sampl
place
rnalat
qiagen
day
rnalat
remov
sampl
homogen
ml
trizol
subsequ
rna
extract
upon
thaw
ml
chloroform
ad
vial
vortex
centrifug
g
min
rna
contain
aqueou
phase
ml
collect
sampl
pass
qiashredd
column
qiagen
g
minut
homogen
remain
genom
dna
aqueou
phase
rna
purifi
use
rneasi
kit
qiagen
describ
previous
except
rna
sampl
treat
dnase
extract
aliquot
sampl
rna
use
quantifi
three
sarscov
strain
urbani
rna
extract
viral
stock
sarscov
urbani
strain
serial
dilut
use
standard
curv
three
qpcr
plate
agpathid
one
step
pcr
kit
ambion
util
publish
sarscov
primer
probe
qpcr
master
mix
prepar
accord
manufactur
recommend
ambion
viral
gene
express
express
pfu
equival
per
mg
total
rna
lung
tissu
five
nanogram
rna
sampl
tissu
compar
viral
rna
level
within
group
anim
process
accord
manufactur
instruct
use
wtovat
tm
pico
system
rna
amplif
system
nugen
inc
sampl
fragment
label
accord
manufactur
instruct
standard
format
antisens
genechip
array
nugen
inc
sampl
hybrid
onto
affymetrix
genechip
rhesu
macaqu
genom
array
affymetrix
accord
manufactur
recommend
chip
scan
use
affymetrix
genechip
scanner
creat
imag
file
dat
genechip
oper
softwar
gco
use
convert
imag
file
cell
intens
data
cel
file
cel
file
input
partek
genom
suit
softwar
partek
inc
st
loui
mo
quantil
normal
produc
signific
probe
set
list
signific
level
multipl
test
correct
use
fals
discoveri
rate
method
determin
probe
set
pvalu
function
annot
signific
differenti
express
gene
identifi
use
ingenu
pathway
analysi
ipa
ingenu
system
microarray
data
deposit
gene
express
omnibu
http
wwwncbinlmnihgovgeo
accord
propos
miam
standard
